HCMT
CORT icon

Highland Capital Management (Tennessee)’s Corcept Therapeutics CORT Stock Holding History

Highland Capital Management (Tennessee)’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,512
Closed -$209K – 426
2025
Q3 		$209K Buy
+2,512
New +$182K 0.01% 400

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Highland Capital Management (Tennessee)'s CORT Position: Q4 2025 in Review

Highland Capital Management (Tennessee) sold out of Corcept Therapeutics (CORT) in Q4 2025, closing a stake of 2,512 shares — an estimated $209K sold.

Highland Capital Management (Tennessee) first reported a position in CORT in Q3 2025 and held it in 1 quarter. The position peaked at $209K in Q3 2025. 389 funds tracked by Wall St. Rank hold CORT as of Q4 2025.

  • Highland Capital Management (Tennessee) reported no remaining Corcept Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Highland Capital Management (Tennessee) sold 2,512 Corcept Therapeutics shares in Q4 2025, an estimated $209K.
  • Highland Capital Management (Tennessee) first reported a position in Corcept Therapeutics in Q3 2025 and held it in 1 quarter.
  • Highland Capital Management (Tennessee)'s Corcept Therapeutics position peaked at $209K in Q3 2025.
  • 389 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2025.

Based on Highland Capital Management (Tennessee)'s 13F filing for Q4 2025, filed 2 Feb 2026.